Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Exclusive distribution and licensing agreement signed for the commercialization of Helsinn's compound currently in development for the treatment of cancer anorexia-cachexia syndrome in non-small cell lung cancer (NSCLC) patients 

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

Anamorelin is a cutting-edge novel, oral, once-daily drug in development for the treatment of cancer anorexia-cachexia syndrome ("CACS"). Current phase III studies are designed to assess safety and efficacy in increasing body weight, lean body mass, muscle strength, and patients' quality of life. The studies' focus is non-small cell lung cancer and is near completion.

Under the terms of the agreement, Helsinn will retain all the development activities (Chemistry, Manufacturing and Controls, preclinical and clinical) and the supply of anamorelin for commercial use. GEN Ilaç will be responsible for regulatory approval as well as commercial activities within their territory.

Riccardo Braglia, CEO of Helsinn Group, said: "We are delighted to be taking our first significant steps into Turkey for anamorelin with a company with the reputation and reach of GEN Ilaç. Medicines like anamorelin, which target therapy areas of significant unmet need such as CACS, will help to improve the quality of life for patients living with cancer and help us deliver on our goal of becoming the world's leading cancer supportive care company."

Abidin Gülmüs, CEO of GEN Ilaç added: "We are proud of our reputation as one of Turkey's leading speciality pharma companies and we are excited to have a successful partnership with Helsinn. We look forward to providing anamorelin to oncologists for the treatment of patients who are suffering from CACS."

SOURCE Helsinn Group